TEVA Earnings Preview: Q2 2026 on April 29

Teva Pharmaceutical Industries Limited (TEVA) will report second quarter 2026 earnings on April 29 after market close. Analysts expect earnings per share of $0.50 and revenue of $3.79 billion. The pharmaceutical giant has shown mixed results recently, beating on earnings in three of the last four quarters while missing revenue expectations. With a market cap of $36.41 billion and stock price at $31.26, investors are watching closely to see if Teva can maintain momentum in its generic and specialty drug business. The company’s Meyka AI grade of B+ reflects solid fundamentals despite some valuation concerns.

What Analysts Expect from Teva Earnings

Wall Street is looking for Teva to deliver $0.50 in earnings per share and $3.79 billion in revenue for the quarter. These estimates represent a significant decline from the previous quarter’s actual results.

EPS Estimate Analysis

The $0.50 EPS estimate is notably lower than the $0.96 reported in Q1 2026 and the $0.66 from Q4 2025. This 48% drop from last quarter suggests analysts expect seasonal weakness or operational challenges. However, it’s important to note that Teva beat the $0.65 EPS estimate in Q1, delivering $0.96 actual earnings. This track record of beating EPS expectations could work in the company’s favor.

Revenue Estimate Breakdown

The $3.79 billion revenue estimate falls short of recent quarters. Q1 2026 brought in $4.71 billion, while Q4 2025 generated $4.48 billion. The estimated decline reflects typical seasonal patterns in the pharmaceutical industry. However, Teva has missed revenue estimates in three of the last four quarters, which could signal ongoing challenges in market demand or pricing pressures in generic drugs.

Historical Performance and Beat/Miss Pattern

Teva’s recent earnings history reveals a company that beats on earnings but struggles with revenue expectations. Understanding this pattern helps predict the April 29 results.

Earnings Per Share Track Record

Teva has beaten EPS estimates in three of the last four quarters. In Q1 2026, the company delivered $0.96 versus the $0.65 estimate, a 48% beat. Q4 2025 saw $0.66 actual versus $0.63 estimate, a modest 5% beat. Q3 2025 missed with $0.372 versus $0.68 estimate. This suggests strong operational execution despite revenue headwinds. If this pattern holds, Teva could beat the $0.50 estimate.

Revenue Miss Streak

Revenue performance tells a different story. Teva has missed revenue estimates in three consecutive quarters. Q1 2026 brought $4.71 billion versus $3.90 billion estimate, but this was an outlier. Q4 2025 delivered $4.48 billion versus $4.44 billion estimate, a narrow beat. Q3 2025 missed with $4.48 billion versus $4.44 billion estimate. The current $3.79 billion estimate appears conservative, suggesting potential upside if Teva maintains pricing power.

Key Metrics and What to Watch

Beyond the headline numbers, several metrics will determine whether Teva’s earnings beat or miss expectations and signal future growth.

Gross Margin Trends

Teva’s gross margin has been expanding, growing 19.5% year-over-year. Watch for margin maintenance as the company faces generic drug pricing pressure. A margin above 51% would signal pricing discipline. The company’s operating margin of 12.5% also matters, as it shows operational efficiency. Any decline here could indicate rising costs or competitive pressures.

Cash Flow Generation

Operating cash flow per share stands at $1.44, while free cash flow per share is $0.99. Investors should monitor whether the company maintains cash generation despite lower revenue estimates. Strong cash flow supports the company’s ability to invest in specialty drugs like Copaxone and AJOVY, which command higher margins than generic products.

Specialty Drug Performance

Teva’s specialty pharmaceutical segment, including migraine treatment AJOVY and tardive dyskinesia drug AUSTEDO, drives higher margins. Watch for commentary on these products’ growth rates. The respiratory portfolio (ProAir, QVAR) also matters significantly. Any weakness in specialty drugs would be concerning for long-term growth prospects.

Meyka AI Grade and Investment Outlook

Meyka AI rates TEVA with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

What the B+ Grade Means

The B+ rating reflects a company with solid fundamentals but some concerns. Teva’s return on equity of 19.95% exceeds many peers, indicating efficient capital use. However, the debt-to-equity ratio of 2.20 raises concerns about leverage. The price-to-earnings ratio of 25.84 suggests the stock trades at a premium to historical averages, limiting upside potential.

Analyst Consensus

All 11 analysts covering Teva rate the stock as a buy, with a consensus rating of 4.0 out of 5. This unanimous bullish stance reflects confidence in the company’s specialty drug pipeline and generic drug stability. However, the lack of price targets suggests uncertainty about fair value. Investors should use the B+ grade as one data point among many when making decisions.

Final Thoughts

Teva Pharmaceutical faces a critical earnings test on April 29 with $0.50 EPS and $3.79 billion revenue estimates. The company’s strong track record of beating EPS expectations suggests potential upside, but three consecutive revenue misses raise concerns about market demand. Investors should focus on specialty drug growth, margin trends, and cash flow generation. With an analyst consensus of buy and Meyka AI’s B+ grade, the market remains constructive on Teva’s long-term prospects despite near-term valuation concerns. The stock’s 2% gain ahead of earnings reflects cautious optimism.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.